MeritValue

Pharmagreen Biotech Inc.

PHBIdata completeness 63%5 fiscal years on file
i. The business — what you’d actually own
FigureFY 2018FY 2019FY 2020FY 2021FY 2022
Revenue—————
Net income−$1.07M1−$767,5372−$2.48M3−$4.53M4−$875,5054
Operating cash flow−$785,5345−$317,8326−$607,6347−$206,0818−$426,5688
Capital expenditure$251,3109$196,12710———
Free cash flow (derived)−$1.04M5,9−$513,9596,10———
Total debt——$30,02811——
Cash & equivalents—$62,68212$12,19612$25,30012$8,01613
Diluted shares293.1M364.9M388.4M326.0M218.7M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom). A derived or summed figure cites every filing line it was built from.

ii. Your slice — ownership made literal
If you owned
shares
Net assets behind them
−$0.08
your share of equity
Profit it earned you last year
−$0.04
Free cash flow it threw off
—
Debt you’d be carrying
—

10 shares is a claim on −$0.08 of net worth that earned you −$0.04 last year.

iii. Is this a good business?
Moat signal · return on equity
— avg · 5y

Not enough data in the filings for a return-on-capital reading.

seeing a moat in the numbers →
Management signal · capital allocation
−25% shares · 5y

Share count is down 25% over 5 years — management has been buying back stock, quietly handing owners a bigger slice. Total debt has held roughly steady.

reading capital allocation →

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth —

Different models answer different questions — which to trust when →

Beyond this page

This page is free, and so is every other company on MeritValue.

In your AI assistant

Connect the MeritValue MCP server to Claude or another MCP client, ask about Pharmagreen Biotech Inc., and get these exact figures with their filing receipts — not an improvised DCF.

Get a free key →
Screen by model

Pull the companies with a published value under any model (up to 500 a request, filtered by data completeness) into your own sheet or agent. Screening is what Analyst adds, at $9/month.

See pricing →
On iPhone

Follow PHBI and keep your own price beside the value. The same engine, with the same receipts.

MeritValue on the App Store →
Sources — the receipts
  1. 10-K filed 2019-12-30 · period ending 2018-09-30 · accession 0001273511-19-000126 (NetIncomeLoss)
  2. 10-K filed 2021-01-08 · period ending 2019-09-30 · accession 0001273511-21-000011 (NetIncomeLoss)
  3. 10-K filed 2021-12-29 · period ending 2020-09-30 · accession 0001477932-21-009538 (NetIncomeLoss)
  4. 10-K filed 2023-01-17 · periods ending 2021-09-30, 2022-09-30 · accession 0001477932-23-000296 (NetIncomeLoss)
  5. 10-K filed 2019-12-30 · period ending 2018-09-30 · accession 0001273511-19-000126 (NetCashProvidedByUsedInOperatingActivities)
  6. 10-K filed 2021-01-08 · period ending 2019-09-30 · accession 0001273511-21-000011 (NetCashProvidedByUsedInOperatingActivities)
  7. 10-K filed 2021-12-29 · period ending 2020-09-30 · accession 0001477932-21-009538 (NetCashProvidedByUsedInOperatingActivities)
  8. 10-K filed 2023-01-17 · periods ending 2021-09-30, 2022-09-30 · accession 0001477932-23-000296 (NetCashProvidedByUsedInOperatingActivities)
  9. 10-K filed 2019-12-30 · period ending 2018-09-30 · accession 0001273511-19-000126 (PaymentsToAcquirePropertyPlantAndEquipment)
  10. 10-K filed 2021-01-08 · period ending 2019-09-30 · accession 0001273511-21-000011 (PaymentsToAcquirePropertyPlantAndEquipment)
  11. 10-K filed 2021-01-08 · period ending 2020-09-30 · accession 0001273511-21-000011 (LongTermDebtNoncurrent)
  12. 10-K filed 2021-12-29 · periods ending 2019-09-30, 2020-09-30, 2021-09-30 · accession 0001477932-21-009538 (CashAndCashEquivalentsAtCarryingValue)
  13. 10-K filed 2023-01-17 · period ending 2022-09-30 · accession 0001477932-23-000296 (CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents)